MYH9 disorder: Identification and a novel mutation in patients with macrothrombocytopenia.
Rungrote NatesirinilkulDarintr SosothikulPatcharee KomwilaisakBunchoo PongtanakulNattee NarkbunnumNajwa YudhasompopPimsiri MekjarusgoolPimjai NiparuckKochawan BoonyawatShinji KunishimaNongnuch Sirachainannull nullPublished in: Pediatric blood & cancer (2021)
The diagnosis of MYH9 disorder is guided by recognizing granulocyte Döhle body-like inclusion bodies and large/giant platelets in the peripheral blood smear. Immunofluorescence study of nonmuscle myosin heavy chain IIA is a sensitive screening method for diagnosis of MYH9 disorder. The diagnosis can then be confirmed by genetic analysis. A total of 67 patients with macrothrombocytopenia were included, of which 11 patients (16%), aged 4 months to 22 years, were ultimately diagnosed with MYH9 disorder. One novel mutation in exon 30 at c.4338T>C (p.F1446A) was detected. This mutation was associated with nonhematologic manifestations presenting in late adolescence with cataracts, hearing loss, and hematuria.
Keyphrases
- hypertrophic cardiomyopathy
- peripheral blood
- end stage renal disease
- hearing loss
- newly diagnosed
- ejection fraction
- chronic kidney disease
- left ventricular
- peritoneal dialysis
- depressive symptoms
- pulmonary tuberculosis
- heart failure
- case report
- mycobacterium tuberculosis
- patient reported outcomes
- atrial fibrillation